Viking Therapeutics, Inc. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $0 and diluted EPS of -$1.55. It usually reports 28–42 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 10, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 11, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
|
-183
-101.8%
|
-1.55
-91.4%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
|
-128
-95.3%
|
-1.10
-89.7%
|
|
Apr 29, 2026
29 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
|
-158
-247.0%
|
-1.37
-234.1%
|
|
Feb 11, 2026
42 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
|
-158
-345.2%
|
-1.38
-334.8%
|
|
Oct 22, 2025
22 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-91
-264.0%
|
-0.81
-268.2%
|
|
Jul 23, 2025
23 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
|
-66
-194.7%
|
-0.58
-190.0%
|
|
Apr 23, 2025
23 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
0
|
-46
-66.8%
|
-0.41
-57.7%
|
|
Feb 5, 2025
36 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
|
-35
-43.9%
|
-0.32
-29.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1607678
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.